Evoke Pharma, Inc.
EVOK
$3.30
$0.216.80%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 97.84% | 100.35% | 110.79% | 110.49% | 106.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 97.84% | 100.35% | 110.79% | 110.49% | 106.51% |
| Cost of Revenue | 76.57% | -10.81% | -41.25% | -38.79% | -45.51% |
| Gross Profit | 98.70% | 109.67% | 129.32% | 134.26% | 132.85% |
| SG&A Expenses | 23.33% | 28.50% | 28.23% | 24.37% | 27.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.53% | 25.63% | 23.44% | 19.39% | 22.50% |
| Operating Income | 29.96% | 18.67% | 17.80% | 14.11% | 4.56% |
| Income Before Tax | 31.31% | 19.21% | 17.66% | 14.04% | 5.25% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.31% | 19.21% | 17.66% | 14.04% | 5.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.31% | 19.21% | 17.66% | 14.04% | 5.25% |
| EBIT | 29.96% | 18.67% | 17.80% | 14.11% | 4.56% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 84.72% | 59.49% | 43.06% | 27.24% | 11.88% |
| Normalized Basic EPS | 84.72% | 59.49% | 43.06% | 27.24% | 11.88% |
| EPS Diluted | 84.72% | 59.49% | 43.06% | 27.31% | 12.10% |
| Normalized Diluted EPS | 84.72% | 59.49% | 43.06% | 27.24% | 11.88% |
| Average Basic Shares Outstanding | 530.99% | 244.15% | 143.54% | 44.94% | 6.36% |
| Average Diluted Shares Outstanding | 530.99% | 244.15% | 143.54% | 44.94% | 6.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |